Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: NeuroOne develops and commercializes thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, monitoring, ablation, and stimulation. The company holds FDA 510(k) clearance for four devices, including the Evo Cortical, Evo sEEG, and OneRF Ablation systems. It operates under a distribution agreement with Zimmer, Inc. for its brain-related products.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2026 | Six Months Ended Mar 31, 2025 |
|---|---|---|
| Product Revenue | $5,283,820 | $4,660,717 |
| License Revenue | $0 | $3,000,000 |
| Total Revenue | $5,283,820 | $7,660,717 |
| Product Gross Profit | $2,854,445 (54.0% margin) | $2,697,950 (57.9% margin) |
| Net Loss | $(3,523,559) | $(485,285) |
| Cash and Cash Equivalents (End of Period) | $2,804,011 | $1,320,251 |
| Operating Cash Flow | $(4,444,546) | $151,905 |
| Financing Cash Flow | $757,445 | $(264,109) |
| Total Liabilities | $2,491,322 | $3,713,125 |
| Warrant Liability | $709,507 | $1,266,894 |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue decreased significantly year-over-year due to the absence of a $3.0 million one-time license fee recognized in the prior period from the Zimmer distribution agreement. However, product revenue increased by 13.4% ($623,103) driven by sales of OneRF products.
- Profitability: The net loss widened substantially to $3.5 million from $0.5 million in the prior year, primarily due to the loss of the license revenue offsetting operating expenses.
- Gross Margin: Product gross margin percentage declined from 57.9% to 54.0%, attributed to higher component costs and a change in sales mix.
- Warrant Liability: The fair value of the warrant liability decreased by $557,387 (from $1.27M to $0.71M), resulting in a $0.2 million benefit in the current period compared to a $0.8 million benefit in the prior period.
- Capital Structure: The company completed a 6-for-1 reverse stock split effective April 15, 2026. All financial data in this filing has been retroactively adjusted to reflect the split.
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. With an accumulated deficit of $82.1 million and cash of $2.8 million, the company believes current resources will fund operations only through September 2026. Additional capital raising is required.
- Recent Financing: In March 2026, the company raised $670,400 via a private placement with a newly appointed officer. No shares were sold under the At-The-Market (ATM) program during the current period.
- Product Development: The company completed a limited market release of the OneRF TN Ablation System in March 2026 and is evaluating distribution options. Development continues on drug delivery capabilities using sEEG technology.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting due to insufficient segregation of duties within the accounting function. Remediation plans are underway.
- Risk Factors: Key risks include dependence on a single customer (Zimmer) for 99.7% of product revenue, reliance on third-party manufacturers, and the uncertainty of future capital availability.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" disclosure and the projection that cash will last only through September 2026.
- Customer Concentration: Assess the risk associated with 99.7% of product revenue coming from a single customer (Zimmer) and the terms of the distribution agreement.
- Reverse Stock Split Impact: Confirm the post-split share count (8,619,876 shares as of May 8, 2026) and the impact on liquidity and trading status on Nasdaq.
- Warrant Liability Volatility: Monitor the fair value adjustments of the warrant liability, which significantly impacts net income/loss but is a non-cash item.
- Internal Control Remediation: Review future filings for updates on the remediation of the material weakness regarding segregation of duties.